# Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage

> **NCT02359162** · PHASE3 · TERMINATED · sponsor: **Sun Yat-sen University** · enrollment: 50 (actual)

## Conditions studied

- Lymphoma, Extranodal NK-T-Cell

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Pegaspargase
- **DRUG:** Etoposide
- **DRUG:** Vincristine
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Prednisone
- **RADIATION:** IMRT

## Key facts

- **NCT ID:** NCT02359162
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-05
- **Primary completion:** 2017-06
- **Final completion:** 2017-06
- **Target enrollment:** 50 (ACTUAL)
- **Why stopped:** The study is out of date
- **Last updated:** 2018-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02359162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02359162, "Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02359162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*